Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 2.61 USD -5.78% Market Closed
Market Cap: 1B USD

Wall Street
Price Targets

IOVA Price Targets Summary
Iovance Biotherapeutics Inc

Wall Street analysts forecast IOVA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IOVA is 8.52 USD with a low forecast of 1.52 USD and a high forecast of 17.85 USD.

Lowest
Price Target
1.52 USD
42% Downside
Average
Price Target
8.52 USD
226% Upside
Highest
Price Target
17.85 USD
584% Upside
Iovance Biotherapeutics Inc Competitors:
Price Targets
CVAC
CureVac NV
3% Upside
301047
Sino Biological Inc
12% Upside
STOK
Stoke Therapeutics Inc
2% Downside
TGTX
TG Therapeutics Inc
48% Upside
OPK
OPKO Health Inc
173% Upside
ATX
Amplia Therapeutics Ltd
152% Upside
EXAS
Exact Sciences Corp
1% Downside

Revenue
Forecast

Revenue Estimate
Iovance Biotherapeutics Inc

The compound annual growth rate of Iovance Biotherapeutics Inc's revenue for the next 4 years is 50%.

N/A
Past Growth
50%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Iovance Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Iovance Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-71%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IOVA's stock price target?
Price Target
8.52 USD

According to Wall Street analysts, the average 1-year price target for IOVA is 8.52 USD with a low forecast of 1.52 USD and a high forecast of 17.85 USD.

What is Iovance Biotherapeutics Inc's Revenue forecast?
Projected CAGR
50%

The compound annual growth rate of Iovance Biotherapeutics Inc's revenue for the next 4 years is 50%.

Back to Top